More good news! Our founding partner Nick Naclerio, has been named a 2026 Founder Champion. This is in addition to the firms recognition as one of Inc.’s Founder-Friendly investors. This honor recognizes Nick’s commitment to helping founders realize their ambitions, build lasting companies, and celebrate milestones along the way.
Illumina Ventures was named to Inc.’s 2026 Founder-Friendly Investors list, recognizing the firm’s commitment to supporting founders as they build and grow their companies. Thank you to the founders who trust us to work alongside them—and to our team for earning that trust every day. Helping founders and their teams turn bold ideas into thriving companies is what we love to do.
Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering.
NuCicer named to 2026 Norrsken100, the list of most promising early-stage companies solving global problems at scale. Founded to be the "Nobel Prize for impact," the Norrsken100 draws from 1,400+ nominations. Honorees are vetted for having a product in market and using scalable technology to solve massive global environmental and social challenges with measurable impact.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
